Breaking News
Get 40% Off 0
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas tool Copy Portfolio
Close

Seres Therapeutics Inc (MCRB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Seres Therapeutics Inc's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.9199 -0.0045    -0.49%
17/05 - Closed. Currency in USD ( Disclaimer )
After Hours
0.8860
-0.0339
-3.6852%
19:52:40 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 1,979,435
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 0.9010 - 0.9985
Seres Therapeutics Inc 0.9199 -0.0045 -0.49%

Seres Therapeutics Inc Company Profile

 
Get an in-depth profile of Seres Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

431

Equity Type

ORD

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn’s disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Contact Information

Address 101 Cambridgepark Drive
Cambridge, 02140
United States
Phone 617 945 9626
Fax -

Top Executives

Name Age Since Title
Richard N. Kender 68 2014 Independent Director
Eric D. Shaff 48 2014 President, CEO & Director
Dennis Arthur Ausiello 79 2015 Independent Director
Mark H. Wilcox - 2015 Member of Scientific Advisory Board
Andrew Goodman - - Member of Scientific Advisory Board
Curtis Huttenhower - - Member of Scientific Advisory Board
Willard H. Dere 70 2017 Independent Director
Kurt C. Graves 56 2015 Independent Director
Stephen A. Berenson 63 2019 Independent Chairman
Claire M. Fraser-Liggett 69 2023 Independent Director
Paul R. Biondi 54 2020 Independent Director
Robert Jenq - - Member of Scientific Advisory Board
Marcel R.M. van den Brink - - Member of Scientific Advisory Board
Elhanan Borenstein - - Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MCRB Comments

Write your thoughts about Seres Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Sri Kiran
Sri Kiran May 03, 2024 11:06AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Sorry over valued zone. Not oversold.
Sri Kiran
Sri Kiran May 03, 2024 11:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Quickly burning its cash and also in oversold zone.
Ivan Dujic
Ivan Dujic Apr 27, 2023 3:30AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
In December 2020, when SER-109 passed phase 3, the price rose to $38. Expect it to be at that price again in a month. Analysts will increase the target price after FDA approval.
Szoka Krisztian
Szoka Krisztian Jul 22, 2021 2:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
They develop a new placebo... Great... Trash
sas stas
sas stas Aug 14, 2020 10:30AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
excellent move.
Fred Taylor
Fred Taylor Aug 10, 2020 5:07PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Which 1 is moving up like this 1 tomorrow
Anthony Meunier
Anthony Meunier Aug 10, 2020 2:00PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hopefully not another kodak
derek carlson
derek carlson Aug 10, 2020 2:00PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Overnight skyrocket for no reason, terrible Financials? I'd say so.
sas stas
sas stas Aug 10, 2020 11:03AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
come to daddy
sas stas
sas stas Aug 10, 2020 10:56AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
lets find a good entry point
Hya Laurent
Hya Laurent Aug 10, 2020 10:31AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
shares were halted ?
Mick West
googleMickWest Aug 10, 2020 10:31AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
several times already
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email